CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 126 enrolled
Drug / intervention
Oral Risperidone +1 moredrug
Likely dose
Risperidone in Long-Acting Injectable Form (Consta) 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00330551
NCT00330551Phase 4Completed
CompareCT.gov

Effects of Risperdal Consta Versus Oral Antipsychotic Medication on Clinical and Functional Outcome and Neurocognition in First-episode Schizophrenia

University of California, Los Angeles·interventional·Posted May 29, 2006·Updated Mar 1, 2023

In Brief

A Phase 4 clinical trial evaluating Oral Risperidone and Risperidone in Long-Acting Injectable Form (Consta) for Schizophrenia. Completed, enrolled 126 participants across 1 site.

Detailed Summary

This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH), Janssen Scientific Affairs, LLC

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 29, 2006
Enrollment StartMar 1, 2006
Primary CompletionNov 1, 2012
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 20.1 years ago

Interventions

Oral Risperidonedrug

Patients will be treated with oral risperidone daily, with the dosage determined by treating psychiatrist.

Risperidone in Long-Acting Injectable Form (Consta)drug

Participants will take a 25 mg dosage of injectable risperidone (Risperidone in Long-Acting Injectable Form (Consta)) once every 2 weeks. Dosage will be adjusted if needed.